Platinum+
Currently, there are only Multi Kinase Inhibitors and chemotherapy available for RET+ patients, so no efficient treatment options exist. Therefore, in a situation where there is unmet needs for selective RET inhibitors, the RET+ inhibitor Gavreto, which is newly launched in South Korea this year, will be the optimal treatment that can provide new therapeutic value to RET+ patients. Through this session, we deliver clinical value for RET+ NSCLC as well as RET+ MTC patients through Phase 1/2 ARROW and the ongoing Phase 3 AcceleRET.
| Address | 17th Floor, GT Tower(East), 411, Seocho-daero, Seocho-gu, Seoul | ||
|---|---|---|---|
| Telephone | 82 2 3451 3600 | Fax | |
| Website | https://www.roche.co.kr | korea.roche@roche.com | |
Roche Korea is a Korean affiliate of the pharmaceutical division of Roche Group, a global leader in cancer treatment and personalized healthcare. Since its foundation, it has constantly provided innovative treatments for cancer, the No.1 cause of death in Korea, establishing itself as the nation’s largest cancer-drug provider. It builds all the business activities on Patient-centricity. It works with researchers from nearly 500 medical institutions in Korea for the development of innovative drugs and strives to expand patient access to them. In immunotherapy, a promising field of cancer treatment, it has been able to improve patient access by adding non-small cell lung cancer and urothelial cancer to the reimbursed indications of its immuno-oncology drug Tecentriq through the reimbursement negotiations, where it was able to remove restrictions on the reimbursement, including PD-L1 expression. Its impressive move has been once again observed in July this year when it was able to add extensive-stage small cell lung cancer to the reimbursed indication of its immunotherapy. Roche Korea strives to build a fast and efficient corporate culture by adopting agile methods and practices in its operations to offer innovative drugs to more patients faster. It has been on the list of Korea’s top 100 best workplaces for two years in a row—2018 and 2019—for constantly creating new opportunities for employment and offering better working conditions. Roche Korea is making various endeavors to provide greater treatment options to patients and healthcare professionals and create a better healthcare environment where patients have affordable access to treatment. With bold investment in R&D, it hosts 45% of the oncology trials and 30% of early phase trials, carried out by the global headquarters. Going forward, it will continue to dedicate itself to the development and delivery of novel drugs. Based on the “One Roche” team spirit, shared with Roche Diagnostics Korea, a Korean office of the Diagnostics division, it will provide innovative solutions for personalized healthcare that combine the diagnostics, treatment, and monitoring of diseases, taking the lead in a journey towards a healthier Korea.
GAVRETO is a prescription medicine used to treat certain cancers caused by abnormal rearranged during transfection (RET) gene in adults with non-small cell lung cancer (NSCLC) that has spread and adults with advanced medullary thyroid cancer (MTC) or MTC that has spread who require a medicine by mouth or injection (systemic therapy). GAVRETO is the first and only precision therapy approved by the EMA that includes 1L treatment of patients with RET fusion-positive advanced NSCLC and MTC. GAVRETO is a potent and highly selective CNS-penetrant RET inhibitor and offers robust responses and durable efficacy. Also, it has a tolerability and safety profile that supports long term treatment.
Rozlytrek is a tumour-agnostic medicine that represents a new approach to treating cancer. It is a selective tyrosine kinase inhibitor designed to inhibit the kinase activity of the TRKA/B/C and ROS1 proteins, whose activating fusions drive proliferation in certain types of cancer. Rozlytrek is approved as a once-daily oral medicine for the treatment of NTRK fusion-positive solid tumours and ROS1-positive non-small cell lung cancer in many jurisdictions including Australia, Canada, the EU, Israel, Japan, New Zealand, South Korea, Taiwan and the US, with further regulatory reviews ongoing around the world. Rozlytrek was granted Breakthrough Therapy designation by the US Food and Drug Administration, Sakigake designation for accelerated review by Japan’s Ministry of Health, Labour and Welfare, and Priority Medicines designation by the European Medicines Agency (EMA).
